drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T lymphocytes engineered with a CD19-directed chimeric antigen receptor to recognize and kill CD19-positive B cells in hematologic malignancies, leading to B-cell aplasia and hypogammaglobulinemia.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes engineered to express a CD19‑directed chimeric antigen receptor (with CD3ζ and costimulatory signaling domains) bind CD19 on malignant and normal B cells, triggering T‑cell activation, proliferation, cytokine release, and cytotoxic killing via perforin/granzyme pathways, resulting in depletion of CD19+ cells and consequent B‑cell aplasia and hypogammaglobulinemia.
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT05952804